Safety of diabetes drug use in non-diabetic overweight patients having shoulder replacement surgery

Outcomes were compared between 90-day and 2-year post-operative periods for non-diabetic obese patients using GLP-1 agonists and those not using them.

• The analysis specifically focused on non-diabetic patients undergoing total shoulder arthroplasty.
• Prior studies have largely centered on GLP-1 users with diabetes, leaving a gap in understanding its effects on non-diabetic patients.
• Evaluating GLP-1's role in weight loss rather than glucose control addresses an emerging area of interest.
• The study compared outcomes of GLP-1 users with a matched cohort of obese individuals not using GLP-1.

Simplified